

# Sherril R Davies

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5813602/publications.pdf>

Version: 2024-02-01

54  
papers

15,795  
citations

109137

35  
h-index

143772

57  
g-index

60  
all docs

60  
docs citations

60  
times ranked

21864  
citing authors

#	ARTICLE	IF	CITATIONS
1	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	1.6	7
2	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
3	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	5.8	58
4	Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Research and Treatment, 2020, 179, 197-206.	1.1	53
5	Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. Cell Reports, 2020, 33, 108276.	2.9	83
6	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. Cancers, 2020, 12, 3857.	1.7	8
7	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	13.5	430
8	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability*. Molecular and Cellular Proteomics, 2019, 18, 1630-1650.	2.5	14
9	miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1525-1533.	1.1	14
10	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell, 2019, 177, 1035-1049.e19.	13.5	498
11	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Research, 2018, 78, 2732-2746.	0.4	52
12	The prognostic effects of somatic mutations in ER-positive breast cancer. Nature Communications, 2018, 9, 3476.	5.8	89
13	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports, 2018, 24, 1434-1444.e7.	2.9	73
14	Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nature Protocols, 2018, 13, 1632-1661.	5.5	377
15	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nature Communications, 2017, 8, 14864.	5.8	112
16	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. Journal of Molecular Diagnostics, 2017, 19, 147-161.	1.2	11
17	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Science Signaling, 2017, 10, .	1.6	25
18	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. Journal of Proteome Research, 2017, 16, 4523-4530.	1.8	17

#	ARTICLE	IF	CITATIONS
19	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	80
20	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , 2016, 534, 55-62.	13.7	1,384
21	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12498.	5.8	69
22	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , 2016, 166, 755-765.	13.5	804
23	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1060-1071.	2.5	104
24	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. <i>Clinical Chemistry</i> , 2016, 62, 48-69.	1.5	187
25	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts. <i>Journal of Proteome Research</i> , 2016, 15, 691-706.	1.8	44
26	QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 740-751.	2.5	8
27	Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 45-56.	2.5	68
28	Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays. <i>Methods in Molecular Biology</i> , 2016, 1410, 223-236.	0.4	33
29	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015, 8, 54.	0.7	352
30	Comprehensive Quantitative Analysis of Ovarian and Breast Cancer Tumor Peptidomes. <i>Journal of Proteome Research</i> , 2015, 14, 422-433.	1.8	26
31	Estrogen Receptor Expression Is High but Is of Lower Intensity in Tubular Carcinoma Than in Well-Differentiated Invasive Ductal Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1507-1513.	1.2	3
32	CPTAC Assay Portal: a repository of targeted proteomic assays. <i>Nature Methods</i> , 2014, 11, 703-704.	9.0	150
33	Proteogenomic characterization of human colon and rectal cancer. <i>Nature</i> , 2014, 513, 382-387.	13.7	1,219
34	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1690-1704.	2.5	323
35	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
36	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2402-2412.	3.2	132

#	ARTICLE	IF	CITATIONS
37	Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 379-390.	1.1	122
38	Genome remodelling in a basal-like breast cancer metastasis and xenograft. <i>Nature</i> , 2010, 464, 999-1005.	13.7	1,077
39	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5222-5232.	3.2	676
40	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12909-12914.	3.3	105
41	<i>PIK3CA</i> and <i>PIK3CB</i> Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2009, 69, 3955-3962.	0.4	198
42	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. <i>Journal of Clinical Oncology</i> , 2009, 27, 1160-1167.	0.8	3,730
43	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 736-750.	3.0	1,844
44	A novel tumor necrosis factor- $\beta$ -responsive CCAAT/enhancer binding protein site regulates expression of the cartilage-derived retinoic acid-sensitive protein gene in cartilage. <i>Arthritis and Rheumatism</i> , 2008, 58, 1366-1376.	6.7	12
45	Site-1 protease is essential for endochondral bone formation in mice. <i>Journal of Cell Biology</i> , 2007, 179, 687-700.	2.3	55
46	Computational identification and functional validation of regulatory motifs in cartilage-expressed genes. <i>Genome Research</i> , 2007, 17, 1438-1447.	2.4	30
47	Site-1 protease is essential for endochondral bone formation in mice. <i>Journal of Experimental Medicine</i> , 2007, 204, i28-i28.	4.2	0
48	A promoter element of the CD-RAP gene is required for repression of gene expression in non-cartilage tissues in vitro and in vivo. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 857-868.	1.2	13
49	Alternative Splicing of Type II Procollagen Exon 2 Is Regulated by the Combination of a Weak 5' Splice Site and an Adjacent Intronic Stem-loop Cis Element. <i>Journal of Biological Chemistry</i> , 2005, 280, 32700-32711.	1.6	40
50	In vivo human Cartilage Oligomeric Matrix Protein (COMP) promoter activity. <i>Matrix Biology</i> , 2005, 24, 539-549.	1.5	16
51	Tissue-restricted expression of the <i>Cdrap/Mia</i> gene within a conserved multigenic housekeeping locus. <i>Genomics</i> , 2004, 83, 667-678.	1.3	7
52	Distribution of the Transcription Factors Sox9, AP-2, and [Delta]EF1 in Adult Murine Articular and Meniscal Cartilage and Growth Plate. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 1059-1065.	1.3	35
53	Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. <i>Arthritis and Rheumatism</i> , 1996, 39, 1896-1904.	6.7	235
54	Doxycycline Inhibits Type X Collagen Synthesis in Avian Hypertrophic Chondrocyte Cultures. <i>Journal of Biological Chemistry</i> , 1996, 271, 25966-25970.	1.6	18